Robert G. Maki, MD, PhD
Adjunct Professor of Medicine (Hematology-Oncology)
Department: Medicine
Contact information
Abramson Cancer Center
3400 Civic Center Blvd
Philadelphia, PA 19104
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215 615 1594
Fax: 215 662 2432
Fax: 215 662 2432
Publications
Education:
BA (Integrated Science Program)
Northwestern University , 1985.
PhD (Immunology )
Cornell University Graduate School of Medical Sciences, 1991.
MD (Medicine)
Cornell University Medical College, 1992.
Permanent linkBA (Integrated Science Program)
Northwestern University , 1985.
PhD (Immunology )
Cornell University Graduate School of Medical Sciences, 1991.
MD (Medicine)
Cornell University Medical College, 1992.
Description of Clinical Expertise
Medical OncologySarcomas of Soft tissue and bone
Developmental therapeutics (Phase I)
Clinical trial design & implementation
Desmoid tumor / deep fibromatosis
Angiosarcoma
Ewing sarcoma
Rhabdomyosarcoma
Chondrosarcoma
Osteogenic sarcoma
Desmoplastic small round cell tumor
Undifferentiated pleomorphic sarcoma
Synovial sarcoma
Solitary Fibrous Tumor
Follicular dendritic cell tumor
Leiomyosarcoma
Myxofibrosarcoma
Chordoma
Uterine sarcomas
Description of Research Expertise
I am a medical oncologist with expertise in connective tissue tumors including sarcomas of soft tissue of bone and soft tissue (at least 70 varieties) as well as locally destructive but non metastatic connective tissue tumors such as desmoid tumors and giant cell tumors of tendon sheath or of bone. I have expertise in clinical trial design and translational oncology, with basic science interesting in epigenetics, tumor microenvironment, and metabolism as pertains to these connective tissue tumors.Selected Publications
Blay JY, Palmerini E, Bollard J, Aguiar S, Angel M, Araya B, Badilla R, Bernabeu D, Campos F, Chs CS, Carvajal Montoya A, Casavilca-Zambrano S, Castro-Oliden 5th, Chacon M, Clara-Altamirano MA, Collini P, Correa Genoroso R, Costa FD, Cuellar M, Dei Tos AP, Dominguez Malagon HR, Donati DM, Dufresne A, Eriksson M, Farias-Loza M, Frezza AM, Frisoni T, Garcia-Ortega DY, Gerderblom H, Gouin F, Gomez-Mateo MC, Gronchi A, Haro J, Hindi N, Huanca L, Jimenez N, Karanian M, Kasper B, Lopes A, Lopes David BB, Lopez-Pousa A, Lutter G, Maki RG, Martinez-Said H, Martinez-Tlahuel JL, Mello CA, Morales Perez JM, Moura DS, Nakagawa SA, Nascimento AG, Ortiz-Cruz EJ, Patel S, Pfluger Y, Provenzano S, Righi A, Rodriguez A, Santos TG, Scotlandi K, Mlg S, Soule T, Stacchiotti S, Valverde CM, Waisberg F, Zamora Estrada E, Martin-Broto J.: Corrigendum to "SELNET clinical practice guidelines for bone sarcoma" Critical reviews in oncology/hematology, vol. 174 (2022), 1-10. Crit Rev Oncol Hematol 180: 103827, Dec 2022 Notes: doi: 10.1016/j.critrevonc.2022.103827. Epub 2022 Oct 8.Rosenbaum E, Chugh R, Ryan CW, Agulnik M, Milhem MM, George S, Jones RL, Chmielowski B, Van Tine BA, Tawbi H, Elias AD, Read WL, Budd GT, Qin LX, Rodler ET, Hirman J, Weiden P, Bennett CM, Livingston PO, Ragupathi G, Hansen D, D'Angelo SP, Tap WD, Schwartz GK, Maki RG, Carvajal RD.: A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. Eur J Cancer 176: 155-163, Nov 2022.
Blay, J. Y., Duffaud, F., George, S., Maki, R. G., Penel, N.: Regorafenib for the Treatment of Sarcoma. Curr Treat Options Oncol 23(11): 1477-1502, Nov 2022.
Rosenbaum, E., Chugh, R., Ryan, C. W., Agulnik, M., Milhem, M. M., George, S., Jones, R. L., Chmielowski, B., Van Tine, B. A., Tawbi, H., Elias, A. D., Read, W. L., Budd, G. T., Qin, L. X., Rodler, E. T., Hirman, J., Weiden, P., Bennett, C. M., Livingston, P. O., Ragupathi, G., Hansen, D., D'Angelo, S. P., Tap, W. D., Schwartz, G. K., Maki, R. G., Carvajal, R. D.: A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. Eur J Cancer 176: 155-163, Nov 2022.
Stacchiotti, S., Maria Frezza, A., Demetri, G. D., Blay, J. Y., Bajpai, J., Baldi, G. G., Baldini, E. H., Benjamin, R. S., Bonvalot, S., Bovee, Jvmg, Callegaro, D., Casali, P. G., D'Angelo, S. P., Davis, E. J., Dei Tos, A. P., Demicco, E. G., Desai, J., Dileo, P., Eriksson, M., Gelderblom, H., George, S., Gladdy, R. A., Gounder, M. M., Gupta, A. A., Haas, R., Hayes, A., Hohenberger, P., Jones, K. B., Jones, R. L., Kasper, B., Kawai, A., Kirsch, D. G., Kleinerman, E. S., Le Cesne, A., Maestro, R., Martin Broto, J., Maki, R. G., Miah, A. B., Palmerini, E., Patel, S. R., Raut, C. P., Razak, A. R. A., Reed, D. R., Rutkowski, P., Sanfilippo, R. G., Sbaraglia, M., Schaefer, I. M., Strauss, D. C., Strauss, S. J., Tap, W. D., Thomas, D. M., Trama, A., Trent, J. C., van der Graaf, W. T. A., van Houdt, W. J., von Mehren, M., Wilky, B. A., Fletcher, C. D. M., Gronchi, A., Miceli, R., Wagner, A. J.: Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. Cancer Treat Rev 110: 102455, Nov 2022 Notes: DOI: 10.1016/j.ctrv.2022.102455
Nathenson, M. J., Hu, J., Ratan, R., Somaiah, N., Hsu, R., DeMaria, P. J., Catoe, H. W., Pang, A., Subhawong, T. K., Amini, B., Sweet, K., Feister, K., Malik, K., Jagannathan, J., Braschi-Amirfarzan, M., Sheren, J., Caldas, Y., Moreno Tellez, C., Rosenberg, A. E., Lazar, A. J., Maki, R. G., Benedetto, P., Cohen, J., Trent, J. C., Ravi, V., Patel, S., Wilky, B. A.: Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study. Clin Cancer Res 28(18): 4092-4104, Sep 2022.
Coppock, J. D., Schneider, M. A., Surrey, L. F., Karakousis, G. C., Maki, R. G., Cooper, K.: S100 and CD34 Expressing Mesenchymal Neoplasm With Rare PLEKHH2::ALK Fusion and Response to ALK Inhibition. Am J Surg Pathol 46(9): 1309-1313, Sep 2022.
Maki, R. G., Grohar, P. J., Antonescu, C. R.: Ewing sarcoma and related FET family translocation-associated round cell tumors: A century of clinical and scientific progress. Genes Chromosomes Cancer 61(8): 509-517, Aug 2022.
Attia, S., Bolejack, V., Ganjoo, K. N., George, S., Agulnik, M., Rushing, D., Loggers, E. T., Livingston, M. B., Wright, J., Chawla, S. P., Okuno, S. H., Reinke, D. K., Riedel, R. F., Davis, L. E., Ryan, C. W., Maki, R. G.: A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results. Cancer Med 10, Aug 2022 Notes: doi: 10.1002/cam4.5044. Online ahead of print.
Henry, D. H., Maki, R. G.: Lenalidomide and the Expanding Toolkit to Manage Kaposi Sarcoma. Clin Cancer Res 28(12): 2485-2487, Jun 2022.